Lung Cancer Central

2022 has brought many research updates and approvals in lung cancer.

Significant action is necessary to prioritize early detection of lung cancer through expanded screening for high-risk individuals, according to a consensus statement released today.

Exposure to increased concentrations of airborne particulate matter appeared associated with increased risk for EGFR-mutated non-small cell lung cancer among never-smokers, according to study results presented at ESMO Congress.

In an interview with Healio, Julia Rotow, MD, spoke about the importance of biomarker testing, the best methods to identify these biomarkers and new advances in personalized treatment options for patients

Mental health plays a significant role in overall health, and addressing these concerns is no less important in patients with lung cancer, according to experts.

Within the past decade, data have emerged indicating an effective role of circulating tumor DNA in identifying lung cancer at an early stage and in matching patients with appropriate treatments.

Both visual and quantitative CT assessments of emphysema were associated with greater odds of lung cancer, researchers reported in Radiology.

CHICAGO — Chemoimmunotherapy and immunotherapy alone conferred comparable benefit as first-line therapy for most patients with advanced non-small cell lung cancer and high PD-L1 expression, results presented at ASCO Annual Meeting showed.

A substantial proportion of patients with resected early non-small cell lung cancer who consented to an adjuvant therapy screening trial did not receive adequate lymph node dissection or adjuvant chemotherapy, according to study results.

Healio spoke with Rebecca L. Siegel, MPH, senior scientific direct of surveillance research at the American Cancer Society, to learn more about earlier detection of lung cancer and how it has helped patients increase their odds of survival and helped clinicians effectively treat their patients.